文献速递浆细胞疾病

基于MRD的最佳终点以支持新诊断多发性骨髓瘤中应答适应性的治疗终止

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

该研究利用一项2期临床试验和前瞻性机构数据库的数据,在221例接受四联诱导治疗+自体干细胞移植后、若二代测序MRD连续两次阴性则终止治疗的患者中,比较了5个短期疗效终点对无进展生存(PFS)的预测性能。最佳拟合模型基于持续MRD<10^-5(风险比0.23,95%CI 0.11-0.47),在121例接受MRD指导治疗终止的患者中预测进展/MRD复燃风险也得到类似结果。

要点

  • 在221例接受四联诱导+自体干细胞移植后MRD指导终止治疗的患者中,持续MRD<10^-5是PFS的最佳预测指标。
  • 持续MRD<10^-5模型的风险比为0.23(95%CI 0.11-0.47),AIC为417.2,C统计量为0.757。
  • 在121例接受MRD指导治疗终止的患者中,持续MRD<10^-5对进展/MRD复燃风险的预测也得到类似结果。

核心结论

  • 持续MRD<10^-5是固定疗程治疗背景下PFS的最佳预测指标,并对MRD复燃或进展风险给出最佳预测模型。

研究设计与样本

  • 利用一项2期临床试验和前瞻性机构数据库的数据,纳入221例接受四联诱导治疗+自体干细胞移植后、若二代测序MRD连续两次阴性则终止治疗的患者。
  • 比较5个短期疗效终点:国际骨髓瘤工作组定义的严格完全缓解、MRD<10^-5(单时间点)、MRD<10^-6、持续MRD<10^-5(两次评估至少间隔1年)、持续MRD<10^-6。
  • 为每个疗效终点建立5个平行Cox回归模型,以PFS为结局,用Akaike信息准则(AIC)和Heagerty与Zheng C指数确定最佳拟合模型。
  • 该试验在www.clinicaltrials.gov注册,注册号为#NCT03224507。

主要发现

  • 最佳拟合模型基于持续MRD<10^-5(AIC 417.2;C统计量0.757;风险比0.23;95%CI 0.11-0.47)。
  • 在121例接受MRD指导治疗终止的患者中,预测进展/MRD复燃风险也见到类似结果。

关键数值与推荐

  • 持续MRD<10^-5:风险比0.23(95%CI 0.11-0.47),AIC 417.2,C统计量0.757。
  • 持续MRD定义为两次连续评估至少间隔1年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic success of first-line quadruplet (QUAD) induction therapy and autologous stem cell transplantation (ASCT) has reinvigorated an interest in fixed-duration therapy, yet optimal short-term efficacy end point for treatment cessation is unknown. Using data from a phase 2 clinical trial and a prospective institutional database, we tested the predictive performance of 5 short-term efficacy end points among 221 patients who received QUAD + ASCT followed by treatment cessation if minimal residual disease (MRD) by next-generation sequencing negative for 2 consecutive time points. Efficacy end points tested were International Myeloma Working Group-defined stringent complete response, MRD <10-5 (single data point), MRD <10-6, sustained MRD (S-MRD; 2 consecutive assessments at least 1 year apart) <10-5, and S-MRD <10-6. We built 5 parallel Cox regression models for each efficacy end point with progression-free survival (PFS) as the outcome. Best fitting models were determined using the Akaike information criterion (AIC) and Heagerty and Zheng C-index. The best fitting model (AIC, 417.2; C statistic, 0.757) was based on S-MRD <10-5 (hazard ratio, 0.23; 95% confidence interval, 0.11-0.47). Similar results were seen for predicting the risk of progression/MRD resurgence among 121 patients undergoing MRD-guided treatment cessation. S-MRD <10-5 is the best predictor of PFS and yields the best predictive models for the risk of MRD resurgence or progression in the setting of fixed-duration therapy. This trial was registered at www.clinicaltrials.gov as #NCT03224507.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Giri S, Dhakal B, Callander NS, et al. Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma. Blood. 2025. PMID: 40193714. doi:10.1182/blood.2024027674

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。